Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naïve and Treatment-Experienced HIV Patients in South Korea.

Updated guidelines for the treatment of antiretroviral therapy (ART)-negative patients with human immunodeficiency virus (HIV) recommend integrase strand transfer inhibitor (INSTI)-based regimens. HIV patients are tested for resistance to antiretrovirals, and the reported prevalence of transmitted INSTI resistance remains rare worldwide. However, no data related to INSTI resistance in Korean HIV patients have been reported. We aimed to determine the prevalence of INSTI resistance-related mutations in South Korea. We subjected both ART-naïve (n=58) and ART-experienced Korean HIV patients (n=41) to genotypic resistance analysis and determined a prevalence of INSTI major resistance mutations of 3.4% (n=2) among ART-naïve patients and 22.0% (n=9) among ART-experienced patients. In the former group, both major INSTI resistance cases involved the non-polymorphic E92Q mutation in the integrase strand. Our findings suggest that INSTI resistance testing should be included in the standard resistance screening protocols for Korean HIV patients.